Cargando…
Development of Liposomal Ciprofloxacin to Treat Lung Infections
Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowar...
Autores principales: | Cipolla, David, Blanchard, Jim, Gonda, Igor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810082/ https://www.ncbi.nlm.nih.gov/pubmed/26938551 http://dx.doi.org/10.3390/pharmaceutics8010006 |
Ejemplares similares
-
Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals
por: Cipolla, David, et al.
Publicado: (2015) -
Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug
por: Cipolla, David, et al.
Publicado: (2016) -
Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties
por: Cipolla, David, et al.
Publicado: (2014) -
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
por: Serisier, David J, et al.
Publicado: (2013) -
The potential of liposome–encapsulated ciprofloxacin as a tularemia therapy
por: Hamblin, Karleigh A., et al.
Publicado: (2014)